| Status: Recommended with restrictions | ||||
Ferric maltol (Feraccru®) is recommended as an option for restricted use within NHS Wales. Ferric maltol (Feraccru®) is licensed for the treatment of iron deficiency in adults. Ferric maltol (Feraccru®) is restricted for use in adult patients with inflammatory bowel disease (IBD) who have mild to moderate iron deficiency anaemia (IDA) and have failed on, or are intolerant to, standard oral iron products and are considered suitable for intravenous iron. Ferric maltol (Feraccru®) is not recommended for use within NHS Wales outside of this subpopulation. |
||||
|
||||
Medicine details |
||||
| Medicine name | ferric maltol (Feraccru®) | |||
| Formulation | 30 mg hard capsule | |||
| Reference number | 5116 | |||
| Indication | Treatment of iron deficiency in adults |
|||
| Company | Norgine Pharmaceuticals Ltd | |||
| BNF chapter | Nutrition & blood | |||
| Submission type | Resubmission | |||
| Status | Recommended with restrictions | |||
| Advice number | 1922 | |||
| NMG meeting date | 07/09/2022 | |||
| AWMSG meeting date | 18/10/2022 | |||
| Date of issue | 07/11/2022 | |||
| Scrutiny Panel meeting date | useMuraDefault | |||
| LOWMAG meeting date | useMuraDefault | |||
| OWMAG meeting date | useMuraDefault | |||